Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
about
Genetic and immune features of resectable malignant brainstem gliomas.Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment.Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
P2860
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@ast
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@en
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@nl
type
label
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@ast
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@en
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@nl
prefLabel
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@ast
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@en
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@nl
P2860
P356
P1476
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
@en
P2093
Pierre-Yves Dietrich
Valérie Dutoit
P2860
P356
10.3389/FONC.2016.00256
P407
P577
2016-12-07T00:00:00Z